International staging system for multiple myeloma

Journal of Clinical Oncology

Volumn 23, Issue 15, 2005, Pages 3412-3420

  Greipp, Philip R ^a   Miguel, Jesus San ^a   Dune, Brian G M ^a   Crowley, John J ^a   Barlogie, Bart ^a   Bladé, Joan ^a   Boccadoro, Mario ^a   Child, J Anthony ^a   Harousseau, Jean Luc ^a   Kyle, Robert A ^a   Lahuerta, Juan J ^a   Ludwig, Heinz ^a   Morgan, Gareth ^a   Powles, Raymond ^a   Shimizu, Kazuyuki ^a   Shustik, Chaim ^a   Sonneveld, Pieter ^a   Tosi, Patrizia ^a   Turesson, Ingemar ^a   Westin, Jan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; SERUM ALBUMIN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTE COUNT; AGE; AGED; ANALYSIS OF VARIANCE; ASIA; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPE; FEMALE; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NORTH AMERICA; PATHOLOGY; PREDICTION AND FORECASTING; PROBABILITY; REPRODUCIBILITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; STANDARD; SURVIVAL RATE; URINE;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ASIA; BETA 2-MICROGLOBULIN; CAUSE OF DEATH; CREATININE; EUROPE; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NORTH AMERICA; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; SEX FACTORS; SURVIVAL RATE;

EID: 20644460600     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.242     Document Type: Article

References (41)

1. Carbone PP, Kellerhouse LE, Gehan EA: Plasmacytic myeloma: A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med 42:937-948, 1967
2. Costa G, Engle RL, Schilling A, et al: Melphalan and prednisone: An effective combination for the treatment of multiple myeloma. Am J Med 54:589-599, 1973
3. Dawson AA, Ogston D: Factors influencing the prognosis in myelomatosis. Postgrad Med J 47:635-638, 1971
4. Report of the Medical Research Council's Working Party for Therapeutic Trials in Leukemia: Report on the first myelomatosis trial: Part I. Analysis of presenting features of prognostic importance. Br J Haematol 24:123-139, 1973
5. Chronic Leukemia Myeloma Task Force, National Cancer Institute: Proposed guidelines for protocol studies: II. Plasma cell myeloma. Cancer Chemother Rep 4:145-158, 1973
6. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Cancer 36:842-854, 1975
7. Bataille R, Durie BGM, Grenier J, et al: Prognostic factors and staging in multiple myeloma: A reappraisal. J Clin Oncol 4:80-87, 1986
8. Medical Research Council's Working Party on Leukemia in Adults: Prognostic features in the third MRC myelomatosis trial. Br J Cancer 42:831-840, 1980
9. Merlini G, Waldenström JG, Jayakar SD: A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. Blood 55:1011-1019, 1980
10. Cassuto JP, Krebs BJ, Viot G, et al: Beta 2 microglobulin, a tumor marker of lymphoproliferative disorders. Lancet 2:108-109, 1978
11. Norfolk D, Child JA, Cooper EH, et al: Serum beta 2 microglobulin in myelomatosis: Potential value in stratification and monitoring. Br J Cancer 39:510-515, 1979
12. Bataille R, Durie BGM, Grenier J: Serum beta 2 microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol 55:439-447, 1983
13. 2 microglobulin in myeloma: A Southwest Oncology Group study. Blood 75:823-830, 1990
14. 2 microglobulin produce a sample and powerful myeloma staging system. Blood 80:733-737, 1992
15. 2M-microglobulin predict survival independent of thymidine-kinase and C-reactive protein in multiple myeloma. Blood 81:3382-3387, 1993
16. San Miguel JF, Garcia-Sanz R, Gonzalez M, et al: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448-455, 1995
17. Oewald GW, Kyle RA, Hicks GA, et al: The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380-390, 1985
18. Tricot G, Barlogie B, Jagannath S, et al: Poor prognosis in multiple myeloma is associated with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256, 1995
19. Tricot G, Sawyer JR, Jagannath S, et al: Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659-2666, 1997
20. Avet-Loiseau H, Andree-Ashley LE, Moore D, et al: Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 19:124-133, 1997
21. Shipp MA, Abeloff MD, Antman KH, et al: International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury. J Clin Oncol 17:423-429, 1999
22. Durie BGM, Salmon SE. Recent Advances in Haematology. Edinburgh, United Kingdom, Churchill Livingstone, 1977
23. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
24. Crowley J, McCoy J, LeBlanc M, et al: Extreme regression: A statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from Intergroup trial S9321. Blood 104:3856, 2004 (abstr 5202)
25. Gentleman R, Crowley J: Graphical methods for censored data. J Am Stat Assoc 86:678-683, 1991
26. LeBlanc M, Crowley J: Survival trees by goodness of split. J Am Stat Assoc 88:457-467, 1993
27. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
28. Crowley JJ, McCoy J, LeBlanc M, et al: Extreme regression: A statistical technique for finding good or poor prognostic groups. Blood 104:385b, 2004 (abstr 5202)
29. Kyle RA: Why better prognostic factors for multiple myeloma are needed? Blood 83:1713-1716, 1994
30. Kyle RA: Prognostic factors in multiple myeloma. Stem Cells 13:56-63, 1995
31. San Miguel JF: Overview of prognostic factors in multiple myeloma. Cancer Res Therapy Control 6:97-99, 1998
32. Turesson I, Abildgaard N, Ahlgren T: Prognostic evaluation in multiple myeloma: An analysis of the impact of new prognostic factors. Br J Haematol 106:1005-1012, 1999
33. Modiano MR, Villar-Werstler P, Crowley J, et al: Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group Study 8229. J Clin Oncol 14:974-977, 1996
34. Jacobson J, Hussein M, Barlogie B, et al: A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 122:441-450, 2003
35. Durie BGM, Kyle R, Belch A, et al: Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4:379-398, 2003
36. Johnson DR, Pober JS: Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium. Proc Natl Acad Sci USA 87:5183-5187, 1990
37. Beersma MFC, Bijlmakers MJE, Ploegh HL: Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol 151:4455-4464, 1993
38. Perosa F, Luccarelli G, Prete M, et al: Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma. Br J Haematol 106:987-994, 1999
39. 2- microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol 159:4781-4792, 1997
40. Bologa RM, Levine DM, Parker TS, et al: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 32:107-114, 1998
41. Maire P, Wuarin J, Schibler U: The role of cis-acting promoter elements in tissue-specific albumin gene expression. Science 244:343-346, 1989